MYOM2 and myeloid sarcoma: Moreover, clinical data have demonstrated that patients in whom MS fails to detect M-proteins exhibit improved clinical outcomes, suggesting that MS negativity is a more accurate predictor of prognosis than IFE, and reinforcing its role as a tool for MRD monitoring and as a non-invasive alternative to bone marrow biopsy [29].